Skip to content
Boost Up Blog – Lifestyle
Author:
Ituran Location and Control Ltd
ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the First Quarter of 2026
May 26, 2026
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 7, 2026
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
May 7, 2026
ITURAN LOCATION AND CONTROL LTD. SCHEDULES FIRST QUARTER 2026 RESULTS RELEASE AND CONFERENCE CALL FOR MAY 26, 2026
April 27, 2026
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 30, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $30 Million for the Fourth Quarter of 2025
March 5, 2026
ITURAN PRESENTS FOURTH QUARTER & FULL YEAR 2025 RESULTS
March 5, 2026